Loading current stock analysis…
Loading current stock analysis…
As of 18 Sept 2026, 03:30 pm
Narayana Hrudayalaya Limited is seeking shareholder approval via postal ballot to increase the annual professional fee for Dr. Varun Shetty, a Consultant Surgeon and relative of key directors, from INR 3.60 crore to INR 4.80 crore. This revised fee, effective April 1, 2026, includes an incentive for developing a quaternary care program and is performance-contingent. The e-voting period runs from September 5, 2026, to October 4, 2026.
As of September 18, 2026, the daily trend for Narayana Hrudayalaya Ltd. shares indicates a bullish Supertrend at 1811.06, with the closing price at ₹1928.5. The 20-day Exponential Moving Average (EMA) is 1889.84. However, the monthly trend shows a bearish Supertrend at 2484.4, with a higher ADX of 53.45, suggesting strong but potentially volatile monthly momentum.
As of September 18, 2026, the nearest support level for Narayana Hrudayalaya Ltd. shares is ₹1922.0, which is approximately 0.34% below the current price. The nearest resistance level is ₹1952.41, approximately 1.24% above the current price.
As of September 18, 2026, Narayana Hrudayalaya Ltd. shares have shown varied returns. The year-to-date (YTD) return is 0.0%, indicating no change in price from the start of the year. Over the last 6 months, the return was 14.0%, while the 1-year return was 8.0%. Since the start of trading, the cumulative return is 47.0%.
As of 18 Sept 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Primary driver: Price swings are higher than typical
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹2,683.63 crore | ₹2,593.81 crore | ₹2,151.17 crore | ₹1,643.79 crore | ₹1,507.27 crore |
| Expenses | PEAK₹2,456.81 crore | ₹2,328.88 crore | ₹1,971.22 crore | ₹1,371.03 crore | ₹1,299.78 crore |
| Finance Costs | ₹86.80 crore | PEAK₹91.29 crore | ₹65.03 crore | ₹42.26 crore | ₹45.16 crore |
| Segment Revenue From Operations | PEAK₹2,719.11 crore | ₹2,654.10 crore | ₹2,205.94 crore | ₹1,707.30 crore | ₹1,567.14 crore |
| Inter Segment Revenue | PEAK₹13.07 crore | ₹10.98 crore | ₹8.75 crore | ₹11.13 crore | ₹9.72 crore |
| Segment Profit Before Tax | ₹260.39 crore | ₹295.03 crore | ₹149.06 crore | PEAK₹295.69 crore | ₹231.56 crore |
Narayana Hrudayalaya Ltd.’s quarter ended 30 June 2026 showed continued top-line expansion, but expenses grew faster than revenue, leading to a decline in profit margins. Finance costs remained elevated in absolute terms, while other comprehensive income swung to a loss, adding volatility to total earnings.
Finance costs declined marginally to ₹86.80 crore from ₹91.29 crore in the previous quarter, a reduction of 4.9%. However, they remained nearly double the ₹45.16 crore reported in Q1 FY26. As a percentage of revenue, finance costs edged up to 3.23% from approximately 3.00% a year earlier.
Other comprehensive income (OCI) swung to a loss of ₹13.23 crore in Q1, compared to a gain of ₹96.50 crore in the previous quarter. This ₹109.73 crore swing contributed to a decline in total comprehensive income to ₹194.05 crore from ₹320.49 crore. OCI has been volatile across recent quarters, ranging from a gain of ₹96.50 crore to a loss of ₹13.23 crore.
Basic and diluted earnings per share from continuing operations were both ₹10.20, down 9.1% from ₹11.22 in the previous quarter. The identical basic and diluted EPS across all reported quarters indicates a simple capital structure without dilutive instruments.
Exchange disclosures and regulatory announcements for Narayana Hrudayalaya.
Narayana Hrudayalaya Ltd. will hold a postal ballot on September 5, 2026, to seek shareholder approval for revising the annual professional fee payable to Dr. Varun Shetty from Rs. 4,80,00,000 effective April 1, 2026. Dr. Shetty serves as a Consultant Surgeon and is a relative of Chairman Dr. Devi Prasad Shetty, Executive Vice Chairman Mr. Viren Prasad Shetty, and Non-Executive Director Dr. Anesh Shetty. The voting period for this ordinary resolution under Section 188 of the Companies Act, 2013, concludes on October 4, 2026.
Narayana Hrudayalaya Ltd. will hold a postal ballot on September 5, 2026, to seek shareholder approval for revising the annual professional fee payable to Dr. Varun Shetty, a Consultant Surgeon and relative of Chairman Dr. Devi Prasad Shetty, to Rs. 4.80 crore effective April 1, 2026. The voting period for this ordinary resolution under Section 188 of the Companies Act, 2013, concludes on October 4, 2026.
Narayana Hrudayalaya Limited published newspaper advertisements on September 5, 2026, in Financial Express (English) and Vijayavani (Kannada) for the notice of a Postal Ballot, as required under Regulation 30 of the SEBI Listing Regulations.
Narayana Hrudayalaya Limited seeks shareholder approval via postal ballot to raise the annual professional fee for Dr. Varun Shetty, a Consultant Surgeon and relative of key directors, from INR 3.60 crore to INR 4.80 crore effective April 1, 2026. The revised fee, approved by the Board on May 22, 2026, includes a quaternary care program development incentive and is contingent on performance. E-voting runs from September 5 to October 4, 2026, with results announced on October 6, 2026.
Narayana Hrudayalaya Ltd. has scheduled an in-person one-to-one institutional investor meeting with the team of FSSA Investment Managers on August 20, 2026, in Bangalore, starting at 10:30 AM, to discuss the company.
Narayana Hrudayalaya Limited scheduled a one-on-one investor meeting with FSSA Investment Managers for Thursday, August 20, 2026, at 10:30 A.M. IST in physical mode. The filing, submitted on August 18, 2026, notes that the schedule is tentative and subject to change due to exigencies.
At Narayana Hrudayalaya Limited's 26th Annual General Meeting held August 14, 2026, shareholders approved all 11 resolutions, including adoption of standalone and consolidated financial statements for FY ended March 31, 2026, a dividend of Rs 4.50 per equity share, re-appointment of Dr. Kiran Mazumdar Shaw, reappointment of Ms. Terri Smith Bresenham as Independent Director for a second term, revisions in remuneration for Dr. Devi Prasad Shetty, Mr. Viren Prasad Shetty, and Dr. Emmanuel Rupert, payment of remuneration to non-executive directors, and issuance of debt securities on a private placement basis. Voting results and the Scrutinizer's report dated August 17, 2026 were submitted to BSE and NSE, with remote e-voting held August 11-13, 2026.
Narayana Hrudayalaya Limited held its 26th Annual General Meeting on August 14, 2026, via video conferencing from 11:30 AM to 12:57 PM IST. The meeting covered the company's FY 2025-26 performance, including the acquisition of Practice Plus Group's hospital business in the UK, and addressed shareholder queries on growth, profitability, and financing. Voting results on 11 agenda items will be declared on or before August 18, 2026.
Recent market and company developments associated with Narayana Hrudayalaya.
Trade Spotlight
Mazagon Dock Shipbuilders, Narayana Hrudayalaya, IREDA, Ashok Leyland, State Bank of India, SBI shares, stock market, stock picks, Rachit Khandelwal, BNK Capital, Nifty50, stock recommendations
Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Narayana Hrudayalaya,Balaji Amines,Axis Bank,Cochin Shipyard,Tata Steel,Bank of India,United Spirits,Siemens,Chalet Hotels,Muthoot Finance,PTC Industries,
Kotak Institutional Equities has upgraded Narayana Hrudayalaya to ‘Buy’ with a target price of ₹2,350, implying nearly 29% upside from Friday’s close, citing strong hospital growth and improving prospects for its insurance businesses.
Apollo Tyres share price, Narayana Hrudayalaya share price, Apollo Tyres shares, Narayana Hrudayalaya shares
In a recent proposal, a parliamentary committee has recommended that hospital room charges not exceed the rates of three-star hotels. The substantial growth of private healthcare as an industry has attracted considerable private equity investment, resulting in valuation spikes and shifts in ownership among hospital chains. However, this raises important questions about the accessibility of healthcare for the average person.
Shrikant Chouhan of Kotak Securities has recommended Narayana Hrudayalaya and Mrs Bectors Food Specialities as top picks for today.
Manipal Health Enterprises plans to raise ₹8,000 crore through a fresh issue for debt repayment and expansion. The company's revenue grew strongly in recent years, while margins faced pressure. Its occupancy rate declined, and geographic concentration is noted in Karnataka. The promoter group's stake will decrease after the initial public offering. Investors may consider waiting for post-listing clarity due to aggressive pricing.
Comprehensive Section Breakdown for Narayana Hrudayalaya
Strategic Vision: Delivering healthcare through technology and patient-centricity.
• Advanced technology
• Trusted brand
• Skilled personnel
• Operational discipline
• Compassion
Revenue from operations rose to ₹2,683.63 crore, up 3.5% sequentially from ₹2,593.81 crore in the previous quarter. On a year-on-year basis, revenue increased 78% from ₹1,507.27 crore in the same quarter last year.
Total expenses climbed to ₹2,456.81 crore, a sequential rise of 5.5% from ₹2,328.88 crore. This outpaced revenue growth for the quarter. Over the last four quarters, sequential revenue growth rates were 9%, 31%, 21%, and 3.5%, while expense growth rates were 5.5%, 44%, 18%, and 5.5%. The current quarter marks the second time in this period that expenses grew faster than revenue, following a similar pattern in the third quarter of the prior fiscal year.
Year-on-year, expenses rose 89% from ₹1,299.78 crore, exceeding the 78% revenue growth and indicating margin pressure on an annual basis as well.
Profit before tax (PBT) fell 10.8% sequentially to ₹262.30 crore from ₹294.14 crore, even as revenue increased. The PBT margin declined to 9.77% from 11.34% in the previous quarter.
Segment profit before tax also decreased, dropping 11.7% to ₹260.39 crore from ₹295.03 crore. The difference between segment PBT and reported PBT was ₹1.91 crore in the current quarter, compared to ₹0.89 crore in the prior quarter, indicating that the profit decline originated within the operating segments.
Over the past five quarters, PBT has fluctuated: ₹296.76 crore in Q2 FY26, ₹152.22 crore in Q3 (which included an exceptional item), ₹294.14 crore in Q4, and ₹262.30 crore in the current quarter. No exceptional items were recorded in Q1 FY27.
In its Q1 filing announcement, management described the quarter as a strong start to FY27, with all geographies delivering robust performance. India recorded 17% year-over-year revenue growth, driven by higher patient footfall and a focus on high-end complex procedures. The Integrated Care ecosystem (clinics and insurance) is strengthening patient outreach and the hospital funnel. The Cayman business performed well, supported by the One Health insurance platform, while the UK business remained stable with integration progressing. The net debt to equity ratio stood at 0.42, with foreign currency debt of USD 115 million and GBP 150 million.
Management reported a strong start to FY27, with all geographies delivering robust performance. India saw solid revenue growth of 17% YoY driven by higher patient footfall and a focus on high-end complex procedures, while the expanding Integrated Care ecosystem (clinics and insurance) continues to enhance patient outreach and strengthen the funnel into hospitals. The Cayman business performed well, supported by the One Health insurance platform, and the UK business remained stable with integration progressing well. Management expressed confidence in delivering on expectations for the year, with net debt to equity at 0.42 and foreign currency debt of USD 115 million and GBP 150 million.
Narayana Hrudayalaya’s first quarter saw revenue growth slow while expenses grew faster, leading to a contraction in profit margins. Finance costs remained high in absolute terms, though their share of revenue increased only slightly compared to a year ago. Other comprehensive income swung to a loss, introducing notable volatility into total comprehensive income. The core operating segments continued to generate profit, albeit at a lower level than the previous quarter.
Category: Healthcare Services
Operates a network of hospitals and clinics providing care across various specialties, including cardiology, multispeciality, and superspeciality services.
Key Products & Services: Narayana Health City • Mazumdar Shaw Medical Centre • Rabindranath Tagore International Institute of Cardiac Sciences
Core Thesis: The company's operations are built on combining advanced medical technology with a compassionate, patient-centric approach to deliver accessible healthcare.
• Medical Technology Integration: Leverages advanced medical technology to provide specialized healthcare services. • Patient-Centric Approach: Focuses on the overall well-being of patients, encompassing physical, emotional, and mental health. • Operational Discipline: Maintains operational discipline across its network to ensure efficient service delivery.